|
|
||||||||
1 Department of Pediatrics and 2 Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287; and 3 Division of Neonatology, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98195-6320
| |
ABSTRACT |
|---|
|
|
|---|
Cocaine may cause stroke, intracranial hemorrhage, seizures, and neurobehavioral abnormalities in fetuses, newborns, and adults, and there could be developmental and/or species differences in mechanisms for these cocaine-induced cerebrovascular effects. To evaluate developmental differences in responses to cocaine, we compared the cerebrovascular and metabolic responses to a 2 mg/kg iv cocaine dose in unanesthetized fetal (n = 8, previously reported, direct fetal injection), newborn (n = 6), and adult (n = 12) sheep. We measured cerebral blood flow, mean arterial blood pressure, and arterial and venous O2 content, and we calculated cerebral O2 consumption and cerebral vascular resistance at baseline and at 30 s and at 5, 15, and 60 min after cocaine injection. Cerebral blood flow increased 5 min after injection in the fetus and newborn, but not until 15 min in the adult. In the fetus, cocaine caused a transient cerebral vasoconstriction at 30 s; in all three groups, cocaine caused cerebral vasodilation, which was delayed in the adult. Cerebral metabolic O2 consumption increased 5 min after injection in the fetus and newborn, but not until 15 min after injection in the adult. Arterial O2 content decreased 5 min after injection in the fetus and 15 min after injection in the adult. We speculate that clinical differences in response to cocaine injection may be explained, in part, by these developmental differences in the cerebrovascular and metabolic responses to cocaine.
brain; blood flow; resistance; oxygen content
| |
INTRODUCTION |
|---|
|
|
|---|
COCAINE ABUSE CONTINUES to be a major health problem in the United States (6, 28, 30, 31). Maternal abuse of cocaine has been associated with neonatal stroke, seizures, intracranial hemorrhages, microcephaly, and neurobehavioral abnormalities, but the pathogenesis of these effects remains unknown (4, 6, 7, 14, 28, 31). Newborns may continue to be exposed to cocaine passively via smoke or actively via breast milk. In the adult, cocaine abuse can lead to cerebral hemorrhagic or vasoocclusive injury, resulting in seizures, ischemic attacks, or stroke. Conflicting results from recent animal studies have not yielded a consistent explanation regarding the mechanisms for these cocaine-induced cerebrovascular effects (1, 9, 10, 19, 31). Whereas species and methodological differences may explain some of the conflicting results, we have questioned whether developmental differences may play a role. Therefore, we compared the cerebrovascular responses of a 2 mg/kg iv dose in unanesthetized fetal, newborn, and adult sheep to determine whether the same dose of cocaine without the confounding variable of the uteroplacental circulation would cause cerebral vasodilation at all developmental stages and to determine what, if any, developmental differences there were in the response to cocaine.
| |
METHODS |
|---|
|
|
|---|
All surgical procedures and experimental protocols were approved by our institutional Animal Care and Use Committee.
Animals and Surgical Preparation
Fetuses. Eight mixed-breed fetal sheep comprised the fetal group; their responses to a 2 mg/kg iv cocaine injection were reported previously (14). These fetuses ranged from 131 to 136 (133 ± 1) days gestation and weighed 4,424 ± 362 g.
Newborns and adults.
Six newborn and 12 adult mixed-breed sheep were used for study.
Newborns ranged from 2 to 7 (5 ± 1) days old and weighed
4,733 ± 226 g. Adults were
2 yr of age. The animals were
brought to the animal care facility on the day before the study and
given procaine penicillin (450,000 U im) before surgery. The sheep were anesthetized with pentobarbital sodium (15-20 mg/kg) via a
catheter placed percutaneously in the external jugular vein. Additional pentobarbital sodium (1-2 mg/kg) was administered as needed. All cutaneous sites of entry were prepared with an alcohol-betadine solution.
Physiological Measurements
Regional brain blood flow was measured using the radiolabeled microsphere technique and the least-squares method of differential spectroscopy (13). Approximately 1 × 106 microspheres (0.4 ml) in the fetus and newborn and 2.5 × 106 microspheres (1.0 ml) in the adult, labeled with 153Gd, 114In, 113Sn, 103Ru, 95Nb, or 46Sc (DuPont NEN, Boston, MA), were injected into the left ventricle in the newborn and adult and into the inferior vena cava in the fetus. Microspheres were injected over 30 s, then 5 ml of 0.9% saline were infused. Reference samples were withdrawn from the brachiocephalic artery at a rate of 2.65 ml/min beginning 30 s before the injection and continuing for 1.5 min after the injection was completed. The injections of microspheres were not associated with changes in heart rate (HR), blood pressure, or pulse pressure. This technique provides complete trapping of microspheres by organs, with comparable distribution of spheres in the reference sample (13). After completion of the studies, the animals were killed with an overdose of pentobarbital sodium followed by saturated KCl solution. Catheter positions were checked, and the brain was then removed at the base and divided at the cephalic border of the pons. All supratentorial tissue was pooled, and the radioactivity was counted to calculate cerebral blood flow (CBF). Blood flow was measured separately for the cerebellum and the brain stem (medulla and pons). Radioactivity in blood and tissue samples was determined with a gamma counter (model 5530, Packard Instrument, Downers Grove, IL). All reference blood and tissue samples contained >400 microspheres.Blood samples for pH, respiratory blood gases, Hb concentration, O2 saturation, and hematocrit were withdrawn into heparinized syringes. Blood gas values and pH were measured using a model ABL 30 blood gas analyzer and electrode (Radiometer, Westlake, OH). O2 saturation and Hb concentration were measured using a hemoximeter (model OSM-3, Radiometer). Mean arterial blood pressure (MAP, referenced to amniotic fluid pressure in fetuses) and HR were continuously monitored (model 2400, Gould Instruments, Oxnard, CA) throughout the experiment.
Blood concentrations of cocaine and its metabolites were measured in
arterial blood collected in tubes containing 0.1 ml of enzyme inhibitor
(equal parts of a saturated sodium fluoride solution and a 10%
solution of glacial acetic acid) per 2.0 ml of blood. The blood was
mixed with the inhibitor and centrifuged, and the plasma was stored
frozen (
70°C) until analyzed. Analysis for cocaine and its
metabolites [ecgonine methyl ester (EME) and benzoylecgonine (BE)]
was performed by electron impact gas chromatography-mass spectrometry
(multiple-ion monitoring) after extraction with solid-phase extraction cartridges. Deuterated internal standards were used for
quantitation. The assay gives a linear response across a concentration range of 3.1-1,000 µg/l. The limit of quantitation by this assay was 1.0 µg/l for each analyte (8).
Blood samples for catecholamines (1.5 ml) were withdrawn into
heparinized 3-ml syringes, kept on ice, and then centrifuged at 4°C
for 20 min. The plasma was removed, and samples were stored at
70°C
until analyzed. Fetal samples were measured by HPLC with electrochemical detection, as described by Nishijima et al.
(20). Samples were purified by alumina absorption.
Epinephrine and norepinephrine were oxidized at 650 mV (vs. Ag-AgCl) on
a Bioanalytical Systems vitreous carbon working electrode. An
integrator quantified catechols by internal standardization. The
sensitivity of the assay was 20 ng/l. Newborn and adult catecholamine
samples were shipped on dry ice to Dr. Michael Heymann's laboratory at
the University of California, San Francisco, for analysis by HPLC with
electrochemical detection (15). Briefly, the thawed plasma
samples were extracted by absorption onto acid-washed alumina at pH
8.6, washed, and eluted with 200 µl of 0.1 M perchloric acid. A
precise aliquot of the eluate was injected into the HPLC for analysis.
The mobile phase consisted of 0.1 M sodium phosphate, 100 mg/l EDTA,
and 80 mg/l SDS (pH 3.8) flowing at a rate of 1.0 ml/min. The
catecholamines were separated on an 8 cm × 4.6 mm ID 3-µm
C18 reverse-phase column (ESA, Bedford, MA). The detector
(Coulochem Electrochemical Detector, ESA), with a cutoff voltage of 30 mV and detector voltage of
330 mV, detects catecholamines in amounts
of 20-25 pg per injected sample. The average recovery of each
catecholamine is quite reproducible from day to day, but the recovery
of one catecholamine is quite different from that of another. Thus each
assay is run with a complete external (unextracted) and internal
(extracted from charcoal-treated plasma) standard curve of five
concentrations of each catecholamine of interest. The chromatographs of
plasma samples are compared with the internal standard curve to
determine plasma catecholamine concentrations. The intra- and
interassay coefficients of variation for norepinephrine and epinephrine
are 1.4 and 2.7, respectively.
Experimental Protocol
On the day of the study, the pregnant ewe or the study animal (newborn or adult) was brought to the laboratory, placed in a specially designed study cart, and allowed 1 h to become accustomed to the surroundings. Six measurements were made during each study. For each measurement, blood samples were drawn first, and then microspheres were injected into the left ventricle (in the newborn or the adult) or the inferior vena cava (in the fetus) while a reference sample was withdrawn from the brachiocephalic artery. Two baseline measurements were obtained 15 min apart. Results from these two measurements were averaged to yield a single "baseline" measurement. At 15-30 min after the second baseline, pure cocaine hydrochloride (2 mg/kg in the newborn and adult and 2 mg/kg estimated fetal weight; Sigma Chemical, St. Louis, MO) dissolved in 5 ml of 0.9% saline was injected intravenously over 30 s followed by a 5-ml 0.9% saline flush. The 2 mg/kg dose was chosen to standardize the dose with previous studies (32) and because this dose has been reported to be in the range of those used by human cocaine addicts (16, 24, 32). Three complete measurements were obtained at 30 s and at 5 and 15 min (fetus), and a fourth measurement was obtained at 60 min (newborn and adult) after the cocaine injection.Samples for determination of cocaine, cocaine metabolites (EME and BE), and catecholamines were drawn before administration of cocaine and at 5 and 15 min after the cocaine injection.
Two additional animals in each group were studied using the identical protocol, except, instead of cocaine, they received an injection (5 ml) of 0.9% saline. These animals were used to assess the stability of this awake, unanesthetized preparation over the time course of the study.
Data Analysis and Calculations
Organ blood flow was calculated as follows: (cpmorgan/cpmref) × reference withdrawal rate (ml/min), where cpmorgan and cpmref represent radioactive counts in the organ and reference samples, respectively. Vascular resistance was calculated as MAP
organ blood flow. Arterial O2 content
(CaO2) was calculated as 1.35 × Hb × O2 saturation. Venous O2 content
(CvO2) was calculated similarly. Cerebral metabolic
O2 consumption (CMRO2) was calculated as
(CaO2
CvO2) × CBF. Cerebral O2 delivery was calculated as CaO2 × CBF. Cerebral fractional O2
extraction was calculated as CMRO2
O2 transport.
Differences within groups were tested by ANOVA for repeated measures.
If the F test was significant, specific differences were
tested with the Newman-Keuls test. An unpaired t-test was used to identify differences within groups, specifically, to identify differences in each timed measurement after cocaine injection from the
baseline measurement. Significance was considered at P
0.05. Values are means ± SE.
| |
RESULTS |
|---|
|
|
|---|
Cardiovascular variables (MAP and HR) and arterial blood gases at
baseline and in response to cocaine administration are shown in Table
1. In all three groups, cocaine caused an
immediate increase in MAP, which returned to baseline in the fetus and
newborn after 5 min and remained increased until 15 min in the adult. HR was unchanged in all three groups, as was hematocrit. There was no
change in pH in any of the three groups, whereas there was mild
persistent hypercapnia and hypoxemia in the fetus and transient
hypercapnia and hypoxemia in the adult.
|
CBF and calculated cerebrovascular resistance at baseline and after
intravenous cocaine are shown in Figs. 1
and 2. Cocaine injection caused an
increase in CBF in all three groups, but the increase was observed at 5 min in the fetus and newborn (36 ± 7 and 33 ± 4%,
respectively), whereas in the adult the increase (19 ± 5%) was
observed 15 min after the injection. CBF in the adult remained elevated
at 60 min (21 ± 7%), whereas it returned to baseline at 60 min
in the newborn. Similar trends in blood flow were also observed in
other areas of the brain (Fig. 3). Cerebrovascular resistance (Fig. 2) increased only at 30 s in the
fetus, and all groups showed a decrease in resistance (vasodilation) that was again observed 5 min after injection in the fetus and newborn,
but not until 60 min after injection in the adult.
|
|
|
CMRO2 and CaO2 data are shown in
Table 2. Cocaine injection caused an
earlier and persistent decrease in the CaO2 in the fetus (5 min) compared with the adult (15 min). There were no changes
in CaO2 in the newborn throughout the study.
CMRO2 increased at 5 min in the fetus and newborn, but
the increase did not occur until 15 min in the adult. Cerebral
O2 delivery increased at 5 min in the newborn and at 5 and
15 min in the adult. The fetus showed an increase in cerebral
fractional O2 extraction at 5 min, whereas in the other two
groups there was no change in O2 extraction throughout the
study. This increase could be attributed to the decrease in
CaO2 in the fetus. There was no change in animal
activity in the fetus or the newborn, i.e., seizure activity,
excitability, or changes in behavior. Brief seizure activity was
observed in two of the adult animals immediately after the cocaine
injection, which led to decreases in CaO2,
CMRO2, and O2 transport, with no change in
O2 extraction.
|
Serum catecholamine, cocaine, and cocaine metabolite levels are shown
in Table 3. Cocaine levels increased 5 min after the injection in all three groups. Cocaine was rapidly
metabolized to EME in all three groups, with the EME level remaining
elevated 15 min after cocaine injection. Cocaine and EME levels were
similar in all three groups. However, BE levels were higher in the
adult at 5 and 15 min than in the newborn and fetus, and levels were higher in the newborn than in the fetus. Baseline serum catecholamine (norepinephrine and epinephrine) levels (pg/ml) are similar to previous
studies (14, 21). Cocaine injection caused an
increase in norepinephrine levels in the fetus and newborn but not in
the adult; the percent increase was greatest in the fetus. Epinephrine levels increased in the adult but not in the fetus or newborn.
|
| |
DISCUSSION |
|---|
|
|
|---|
The major findings of this unique comparative study are that cocaine injection causes cerebral vasodilation and increased O2 consumption in fetal, newborn, and adult sheep, but there are developmental differences in the timing of the responses and direct effects of cocaine on systemic oxygenation. The initial cerebral vasoconstriction in the fetus could be a direct effect of the cocaine injection and could subsequently lead to fetal hypoxemia (cerebral vasodilation) and increased CMRO2 (14). We observed a comparative delay in cerebral vasodilation and increased O2 consumption in the adult. Also, EME levels were increased after cocaine administration; this increase could account, in part, for the vasodilation observed in our three groups (22). These findings therefore support the hypothesis that clinical and experimental differences in the cerebral responses to cocaine injection may be explained, in part, by developmental differences.
The mechanism for these developmental differences in the cerebrovascular responses to cocaine is not known. One possibility could be developmental differences in cocaine metabolism. Fetuses and newborns lack the metabolic capabilities of adults, and therefore cocaine levels may remain elevated for a longer period of time, and appearance of cocaine's various metabolites, all of which are vasoactive, may be delayed (12). Indeed, we found significantly higher BE levels in the adult than in the newborn and fetus, and these BE levels persisted. In isolated sheep cerebral arteries, BE causes vasoconstriction (26). It is possible, therefore, that the higher BE levels in the adult contributed to the delayed cerebral vasodilation we observed. However, differential metabolism could not explain the initial vasoconstriction we observed in the fetus while fetal BE levels were very low.
Another possible explanation for the developmental differences we observed could be differences in CMRO2, either intrinsically or in response to cocaine. 1) We observed an increase in CMRO2 after cocaine injection in all three groups, with the increase occurring later in the adult. 2) CMRO2 is closely coupled with CBF (27). 3) The mechanism whereby cocaine increases CMRO2 is not known but likely is related to increased norepinephrine levels. 4) Cocaine blocks the reuptake of norepinephrine and other neurotransmitters (serotonin and epinephrine) at the synaptic cleft (23). Norepinephrine infusion has been shown to increase CMRO2 and CBF in baboons (18). All three developmental groups showed an increase in norepinephrine concentrations after cocaine injection, but there was a trend toward higher levels in the fetus. This could account for a greater cerebral vasodilatory response to cocaine in the fetus than in the adult.
The most likely explanation for the developmental differences in the timing and extent of responses to cocaine could be the transient hypoxemia that was observed in the fetus (not due to uteroplacental vasoconstriction) and in the adult. In our original fetal report, Iida et al. (14) proposed that the fetal hypoxia could be due to increased brain metabolism associated with cocaine-induced seizure activity or changes in behavioral state. One limitation to this study was our inability to see the fetus during the study and to detect any evidence of subclinical seizure activity in this group. We observed no hemodynamic or blood gas changes suggestive of fetal seizures, but we did not measure electroencephalogram activity during our study, so we may have missed evidence of seizure activity. Indeed, in two of our adult sheep we did observe gross seizure activity, but we did not observe such activity in our newborns. Whatever the cause of the hypoxemia, it was temporally related to the cerebral vasodilation we observed after cocaine injection (e.g., 5 min in the fetus and 15 min in the adult).
Our study results support the results of all our previous studies
showing that cocaine injection causes cerebral vasodilation in
developing sheep and in cats (10, 11,
14, 21). Others have shown cerebral
vasoconstriction in vivo and in vitro (1, 2,
11, 17, 21, 26,
29). Stein and Fuller (29) reported results
similar to our studies, in that they observed an increase in CBF in the
rat model as well as a transient increase in blood pressure. Yonetani
et al. (33) showed that an acute cocaine injection caused
a persistent decrease in cortical O2 pressure with a
decrease in CBF and blood pressure. We observed an increase in arterial
blood pressure in all three groups; the fetal results were similar to
our previous observations after maternal cocaine injection
(11). Our group, using a 4 mg/kg dose, previously reported
cerebral vasodilation after a direct cocaine injection in near-term
fetal sheep and in newborn sheep (14, 21) and vasodilation after cocaine injection in unanesthetized newborn sheep
without hypoxemia (21) that was also observed in this study. Others have also shown that cocaine injection is not associated with systemic hypoxemia. Most recently, for example, Burchfield et al.
(5) infused cocaine over 30 min into near-term fetal sheep
(0.2 mg · kg
1 · min
1 for 30 min = 6 mg/kg, levels ~230 ng/ml) and observed no significant hypoxemia or changes in CBF or O2 delivery. We speculated
previously that species and/or methodological differences (route of
injection, anesthesia techniques, or timing of measurements) may
account for these conflicting results in laboratory animals. Now we
could add developmental differences in cerebrovascular or metabolic development to the possible reasons for the conflicting vascular responses to cocaine reported in the literature.
We chose a standard dose of 2 mg/kg rapid intravenous cocaine bolus to compare the cerebrovascular responses at each developmental stage with the same event. This dose is also similar to the dose used by human cocaine addicts (16, 24, 32). However, the metabolism of cocaine is much more rapid in sheep than in humans. In humans the half-life of a single dose of intravenous cocaine in plasma is 48 min (16); in sheep it is 10 min (21). Cocaine and its metabolites have been reported to persist in the urine of adult humans for as long as 60 h after intranasal use (3). Cocaine or cocaine metabolites may have a direct or an indirect effect on the cerebral vascular bed (21, 22). In sheep, cocaine is primarily metabolized to EME; in humans, the major metabolite is BE. EME causes vasodilation in newborn sheep (22) and in isolated cat cerebral arteries (19, 21). EME levels were elevated at 5 min in all three groups in our study, and they remained elevated at 15 min. Therefore, differences in cocaine and cocaine metabolism make it difficult to extrapolate our sheep results to humans.
Although there are certain limitations to our studies, we are the first to use an identical unanesthetized experimental protocol to examine the cerebrovascular and metabolic responses to the same dose of any drug at three developmental periods. The sheep is an ideal animal for these studies because of its multicotyledonary placenta, which allows significant fetal and uterine manipulation without precipitating preterm labor or causing fetal distress. In addition, there are numerous previous cerebral physiological studies for comparison at all developmental stages in sheep.
Overall, the results of this unique comparative sheep study confirm that cocaine causes cerebral vasodilation in sheep of all ages, but we have observed developmental differences in the timing and extent of these responses. Our study results support the hypothesis that clinical and perhaps species variability in cocaine's cerebral vascular effects may be due, in part, to developmental differences.
| |
ACKNOWLEDGEMENTS |
|---|
The authors gratefully acknowledge the excellent technical assistance of Debra Flock and George Kuck, the excellence statistical assistance of Sarah Baker, the additional mentoring of Andrew Harris, and the excellent secretarial and computer support of Tammy Thompson.
| |
FOOTNOTES |
|---|
Address for reprint requests and other correspondence: R. J. Traystman, Anesthesiology/Critical Care Medicine, Johns Hopkins Medical Institutions, 600 North Wolfe St., Blalock 1408, Baltimore, MD 21287 (E-mail: rtraystm{at}jhmi.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Received 26 May 1999; accepted in final form 5 January 2000.
| |
REFERENCES |
|---|
|
|
|---|
1.
Albuquerque, ML,
Kurth CD,
Kim SJ,
and
Wagerle LC.
Cocaine-mediated cerebral vasoconstriction in newborn piglets (Abstract).
Pediatr Res
29:
56A,
1991.
2.
Albuquerque, MLC,
Kurth CD,
Monitto CL,
Shaw L,
and
Anday EK.
Cocaine metabolites affect cerebrovascular tone in newborn piglets (Abstract).
Pediatr Res
31:
57A,
1992.
3.
Ambre, J.
The urinary excretion of cocaine and metabolites in humans.
J Anal Toxicol
8:
241-245,
1985.
4.
Bandstra, ES,
and
Burkett G.
Maternal-fetal and neonatal effects of in utero cocaine exposure.
Semin Perinatol
15:
288-301,
1991[ISI][Medline].
5.
Burchfield, DJ,
Pena A,
Peters AJM,
Abrams RM,
and
Phillips D.
Cocaine does not compromise cerebral or myocardial oxygen delivery in fetal sheep.
Reprod Fertil Dev
8:
383-389,
1996[Medline].
6.
Chasnoff, IJ,
Burns KA,
and
Burns WJ.
Cocaine use in pregnancy: perinatal morbidity and mortality.
Neurotoxicol Teratol
9:
291-293,
1987[ISI][Medline].
7.
Chasnoff, IJ,
Bussey ME,
Savich R,
and
Stack CM.
Perinatal cerebral infarction and maternal cocaine use.
J Pediatr
108:
456-459,
1986[ISI][Medline].
8.
Cone, EJ,
Hillsgrove M,
and
Darwin WD.
Simultaneous measurement of cocaine, cocaethylene, their metabolites, and "crack" pyrolysis products by gas chromatography-mass spectrometry.
Clin Chem
40:
1299-1305,
1994
9.
Covert, RF,
Schreiber MD,
Tebbett IR,
and
Torgerson LJ.
Hemodynamic and cerebral blood flow effects of cocaine, cocethylene and benzoylecgonine in conscious and anesthetized fetal lambs.
J Pharmacol Exp Ther
270:
118-126,
1994
10.
Dohi, S,
Jones MD, Jr,
Hudak ML,
and
Traystman RJ.
Effects of cocaine on pial arterioles in cats.
Stroke
21:
1710-1714,
1990
11.
Gleason, CA,
and
Traystman RJ.
Cerebral responses to maternal cocaine injection in immature fetal sheep.
Pediatr Res
38:
943-948,
1995[ISI][Medline].
12.
Havas, HF,
Dellaria M,
Schiffman G,
Geller EB,
and
Adler MW.
Effect of cocaine on the immune response and host resistance in BALB/c mice.
Int Arch Allergy Appl Immunol
83:
377-383,
1987[ISI][Medline].
13.
Heymann, MA,
Payne BD,
Hoffman JIE,
and
Rudolph AM.
Blood flow measurements with radionuclide-labeled particles.
Prog Cardiovasc Dis
20:
55-79,
1977[ISI][Medline].
14.
Iida, H,
Gleason CA,
O'Brien TO,
and
Traystman RJ.
Fetal responses to acute fetal cocaine injection in sheep.
Am J Physiol Heart Circ Physiol
267:
H1968-H1975,
1994
15.
Iwamoto, HS,
and
Rudolph AM.
Effects of angiotensin II on blood flow and its distribution in fetal lambs.
Circ Res
48:
183-189,
1981
16.
Javaid, JI,
Fischman MW,
Schuster CR,
Kekirmenjian H,
and
Davis JM.
Cocaine plasma concentrations: relation to physiological and subjective effects in humans.
Science
202:
227-228,
1978
17.
Kurth, CD,
Monitto C,
Albuquerque ML,
Fever P,
Anday E,
and
Shaw L.
Cocaine and its metabolites constrict cerebral arterioles in newborn pigs.
J Pharmacol Exp Ther
265:
587-591,
1993
18.
MacKenzie, ET,
McCulloch J,
and
Harper AM.
Influences of endogenous norepinephrine on cerebral blood flow and metabolism.
Am J Physiol
231:
489-493,
1976.
19.
Madden, JA,
and
Powers RH.
Effect of cocaine and cocaine metabolites on cerebral arteries in vitro.
Life Sci
47:
1109-1114,
1990[ISI][Medline].
20.
Nishijima, MK,
Breslow MJ,
Raff H,
and
Traystman RJ.
Regional adrenal blood flow during hypoxia in anesthetized, ventilated dogs.
Am J Physiol Heart Circ Physiol
256:
H94-H100,
1989
21.
O'Brien, TP,
Gleason CA,
Jones MD, Jr,
Cone EJ,
London ED,
and
Traystman RJ.
Cerebral responses to single and multiple cocaine injections in newborn sheep.
Pediatr Res
35:
339-343,
1994[ISI][Medline].
22.
Pane, MA,
Traystman RJ,
and
Gleason CA.
Ecgonine methyl ester, a major cocaine metabolite, causes cerebral vasodilation in neonatal sheep.
Pediatr Res
41:
815-821,
1997[ISI][Medline].
23.
Pitts, DK,
Udom CE,
and
Marwah J.
Neuropharmacology of cocaine: role of monoaminergic systems.
Monogr Neural Sci
13:
34-54,
1987[Medline].
24.
Resnick, RB,
Kestenbaum RS,
and
Schwartz LK.
Acute systemic effects of cocaine in man: controlled study by intranasal and intravenous routes.
Science
195:
696-698,
1977
25.
Ritchie, JM,
and
Greene NM.
Local anesthesia.
In: The Pharmacological Basis of Therapeutics, edited by Gilman AG,
Goodman LS,
and Gilman A.. New York: MacMillan, 1980, p. 300-320.
26.
Schreiber, MD,
Madden JA,
Covert RF,
and
Torgerson LJ.
Effects of cocaine, benzoylecgonine, and cocaine metabolites on cannulated pressurized fetal sheep cerebral arteries.
J Appl Physiol
77:
834-839,
1994
27.
Siesjo, BK.
Brain Energy Metabolism. New York: Wiley, 1987, p. 56-100.
28.
Singer, L,
Arendt R,
and
Minnes S.
Neurodevelopmental effects of cocaine.
Clin Perinatol
20:
245-262,
1993[ISI][Medline].
29.
Stein, EA,
and
Fuller SA.
Cocaine's time action profile on regional cerebral blood flow in the rat.
Brain Res
626:
117-126,
1993[ISI][Medline].
30.
Vega, WA,
Kolody B,
Hwang J,
and
Noble A.
Prevalence and magnitude of perinatal substance exposures in California.
N Engl J Med
329:
850-854,
1993
31.
Volpe, JJ.
Effects of cocaine use on the fetus.
N Engl J Med
327:
399-407,
1992[ISI][Medline].
32.
Woods, JR, Jr,
Plessinger MS,
and
Clark KE.
Effects of cocaine on uterine blood flow and fetal oxygenation.
JAMA
257:
957-961,
1987[Abstract].
33.
Yonetani, M,
Huang C,
Lajevardi N,
Pastuszko A,
Delivoria-Papadopoulous M,
and
Anday E.
Effects of acute cocaine injection on the extracellular level of dopamine, blood flow and oxygen pressure in brain of newborn piglets.
Biochem Med Metab Biol
51:
91-97,
1994[ISI][Medline].
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |